Our findings align with the guideline's emphasis on the importance of NITs for monitoring liver fibrosis and highlight the potential of novel biomarkers, such as PRO‐C3 and GP73, to enhance risk stratification and inform treatment decisions in CHB management. The gene discussed is GOLM1; the disease is Hepatic fibrosis.